Oncology Pharma : Disclosure Statement for the period ended December 31, 2021

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

ONCOLOGY PHARMA, INC.

One Sansome Street

Suite 3500

San Francisco, CA 94104

_______________________________

[phone]

[e-mail] 2834

Quarterly Report

For the Period Ending: December 31, 2021

(the "Reporting Period")

As of December 31, 2021, the number of shares outstanding of our Common Stock was:

33,763,216

As of September 30, 2021, the number of shares outstanding of our Common Stock was:

31,563,216

As of March 31, 2021, the number of shares outstanding of our Common Stock was:

27,338,216

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐

No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐

No: ☒

Indicate by check mark whether a Change in Control1 of the company has occurred over this reporting period:

1 "Change in Control" shall mean any events resulting in:

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

1. The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
2. A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
3. The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the
   OTC Markets Group Inc.

OTC Pink Basic Disclosure Guidelines (v3 February 2021)

Page 1 of 11

Yes: ☐

No: ☒

1. Name and address(es) of the issuer and its predecessors (if any)

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

Oncology Pharma, Inc., Nevada Corporation, Active

SourcingLink.net, Inc., Nevada Corporation until 4/2019

QCS.net Corporation, Delaware Corporation until 7/1999

Parkway Capital Corporation, Colorado, until 6/1994.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

Nevada, Active

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

On October 9, 2020, the Company implemented a decrease in common shares via a 1 for 100 reverse split.

The address(es) of the issuer's principal executive office:

One Sansome Street

Suite 3500

San Francisco, CA 94104

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐

No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

1. Security Information

Trading symbol:

ONPH

surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

OTC Markets Group Inc.
OTC Pink Basic Disclosure Guidelines (v3 February 2021)	Page 2 of 11

Exact title and class of securities outstanding:	Common
CUSIP:	68235J 201
Par or stated value:	$0.001
Total shares authorized:	900,000,000	as of date: December 31, 2021
Total shares outstanding:	33,763,216	as of date: December 31, 2021
Number of shares in the Public Float2:	12,018,031	as of date: December 31, 2021
Total number of shareholders of record:	206	as of date: December 31, 2021

All additional class(es) of publicly traded securities (if any):

Trading symbol:	None
Exact title and class of securities outstanding:
CUSIP:
Par or stated value:
Total shares authorized:		as of date:
Total shares outstanding:		as of date:
Transfer Agent
Name:	Olde Monmouth Stock Transfer Co. Inc.
Phone:	[phone]
Email:	[e-mail]
Address: 200 Memorial Pkwy, Atlantic Highlands, NJ 07716
Is the Transfer Agent registered under the Exchange Act?3 Yes: ☒	No: ☐

1. Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

A. Changes to the Number of Outstanding Shares

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed

fiscal years and any subsequent periods: ☐

See following Table.

1. "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.
2. To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

OTC Markets Group Inc.
OTC Pink Basic Disclosure Guidelines (v3 February 2021)	Page 3 of 11

						Were the
						shares
						issued at a
					Value of	discount to
					shares	market		Reason for share	Restricted
		Number of			issued	price at the	Individual/ Entity Shares were	issuance (e.g. for cash	or
		Shares			($/per	time of	issued to (entities must have	or debt conversion) OR	Unrestricted	Exemption or
	Transaction	Issued (or	Class of		share) at	issuance?	individual with voting / investment	Nature of Services	as of this	Registration
Date of Transaction	Type	cancelled)	Securities	Issuance	(Yes/No)	control disclosed).	Provided (if applicable)	filing?	Type?
Number of Shares outstanding as of April 1, 2019				Common:	1,248,961
							Preferred:	1,000
7/16/2019	New	1,000	common	$	0.01	No	Dr. Stefan Gruenwald	consulting	Restricted	4(a)(2)
							Kalos Therapeutics (Control
8/26/2019	New	25,000	common	$	0.05	No	Person: George Colberg)	Letter of Intent	Restricted	4(a)(2)
9/17/2019	New	85,000	common	$	0.03	No	Dr. Stefan Gruenwald	consulting	Restricted	4(a)(2)
10/30/2019	New	15,000	common	$	0.03	No	George Malasek	consulting	Restricted	4(a)(2)
10/30/2019	New	1,000	common	$	0.03	No	Daniel Chasse	consulting	Restricted	4(a)(2)
10/30/2019	New	5,000	common	$	0.03	No	Dimitrios Theofilopoulos	consulting	Restricted	4(a)(2)
							Bright Star International, Inc.
11/12/2019	New	125,000	common	$	0.03	No	(Control Person Kevin Dills)	Conversion of Debt	Unrestricted	Rule 144
11/12/2019	New	3,000	common	$	0.03	No	Dimitrios Theofilopoulos	consulting	Restricted	4(a)(2)
12/30/2019	Canceled	10,000	common	NA	NA	Vijay Mahant	NA	Restricted	NA
							NanoSmart Pharmaceuticals, Inc
2/26/2020	New	2,500	common	$	0.02	No	(Control Person Henry Smith)	License Fee	Restricted	4(a)(2)
Number of Shares outstanding on April 1, 2020				Common:	1,501,461
							Preferred:	1,000
							Kalos Therapeutics, Inc. (Control
8/11/2020	New	50,000	common	$	0.01	No	Person: George Colberg)	Letter of Intent	Restricted	4(a)(2)
8/18/2020	New	5,000	common	$	0.02	No	Henry Smith	consulting	Restricted	4(a)(2)
8/18/2020	New	5,000	common	$	0.02	No	James R. Smith	consulting	Restricted	4(a)(2)
8/18/2020	New	5,000	common	$	0.02	No	Dr. Argyrios Theofilopoulos, MD	consulting	Restricted	4(a)(2)
10/9/2020	New	515,000	common	$	0.70	No	Dimitrios Theofilopoulos	legal fees	Restricted	4(a)(2)
10/9/2020	New	500,000	common	$	0.70	No	George Malasek	officer compensation	Restricted	4(a)(2)
10/9/2020	New	255	common	$	0.70	No	Cede & Co.	reverse split rounding	Restricted	4(a)(2)
10/9/2020	New	350,000	common	$	0.70	No	James R. Smith	consulting	Restricted	4(a)(2)
10/9/2020	New	350,000	common	$	0.70	No	Dr. Argyrios Theofilopoulos	consulting	Restricted	4(a)(2)
10/9/2020	New	350,000	common	$	0.70	No	Henry Smith	consulting	Restricted	4(a)(2)
10/9/2020	New	10,000,000	common	$	0.70	No	Charles Wagner	director fee	Restricted	4(a)(2)
10/9/2020	New	2,500,000	common	$	0.70	No	Carlos Barnett	director fee	Restricted	4(a)(2)
10/9/2020	New	2,500,000	common	$	0.70	No	Shawn Crouse	director fee	Restricted	4(a)(2)
10/9/2020	New	2,500,000	common	$	0.70	No	Stefan Gruenwald	director fee	Restricted	4(a)(2)
							Bright Star International, Inc.
10/22/2020	New	2,000,000	common	$	0.42	Yes	(Control Person Kevin Dills)	Conversion of Debt	Unrestricted	Rule 144
							Life Sciences Journeys, Inc.
10/27/2020	New	1,000,000	common	$	0.42	Yes	(Control Person Karen Alanis)	Conversion of Debt	Unrestricted	Rule 144
10/30/2020	New	1,000,000	common	$	0.50	No	James B. Smith	officer compensation	Restricted	4(a)(2)
							Life Sciences Journeys, Inc.
2/24/2021	New	1,700,000	common	$	36.50	Yes	(Control Person Karen Alanis)	Conversion of Debt	Unrestricted	Rule 144
							Bright Star International, Inc.
2/25/2021	New	500,000	common	$	39.00	Yes	(Control Person Kevin Dills)	Conversion of Debt	Unrestricted	Rule 144
							Sybleu, Inc. (Control Person
3/22/2021	New	6,500	common	$	36.50	No	David Koos)	License fee	Restricted	4(a)(2)
Number of Shares outstanding on April 1, 2021				Common:	27,338,216
							Preferred:	1,000
							Regen Biopharma, Inc. (Control
4/12/2021	New	50,000	common	$	28.00	No	person: David Koos)	License fee	Restricted	4(a)(2)
							Life Sciences Journeys, Inc.
5/5/2021	New	800,000	common	$	37.48	Yes	(Control person: Kevin Dills)	Conversion of Debt	Unrestricted	Rule 144
							Bright Star International, Inc.
8/4/2021		1,600,000	common	$	21.70	Yes	(Control person: Kevin Dills)	Conversion of Debt	Unrestricted	Rule 144
							Kalos Therapeutics, Inc. (Control		Shares
8/6/2021		(25,000)	common	$	2.17	No	person: George Colberg)	Legal Settlement	Cancelled	Rule 144
OTC Markets Group Inc.						Bright Star International, Inc.
OTC Pink Basic Disclosure	Guidelines (v3	February	2021)		Page	4 of 11
Yes	(Control person: Kevin Dills)	Rule 144
9/22/2021		1,800,000	common		$12.38	Conversion of Debt	Unrestricted
							Bright Star International, Inc.
11/17/2021		2,200,000	common	$	8.05	Yes	(Control person: Kevin Dills)	Conversion of Debt	Unrestricted	Rule 144
Number of Shares outstanding on December 31, 2021				Common:	33,763,216
							Preferred:	1,000

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

OTC Markets Group Inc.
OTC Pink Basic Disclosure Guidelines (v3 February 2021)	Page 5 of 11